Alembic Pharmaceuticals rose 2.27% to Rs 547 at 14:35 IST on BSE after consolidated net profit rose 36.75% to Rs 123.72 crore on a 10.38% increase in total income to Rs 952.20 crore in Q1 June 2019 over Q1 June 2018.
The result was announced during market hours today, 29 July 2019.
Meanwhile, S&P BSE Sensex was down 257.73 points or 0.68% at 37,625.06.
On BSE, 7,544 shares were traded in Alembic Pharmaceuticals counter, compared to a 2-week average of 2,977 shares. The stock hit an intraday high of Rs 559 and an intraday low of Rs 530. It hit a 52-week high of Rs 664 on 27 September 2018 and a 52-week low of Rs 435.10 on 21 June 2019.
The company's EBITDA surged 54% to Rs 233 crore in Q1 June 2019 over Q1 June 2018. The EBITDA margin stood at 25% in Q1 June 2019 as against 18% in Q1 June 2018. The pharmaceutical company received 9 ANDA approvals during the quarter and cumulative ANDA approvals of 98 (including 12 tentative). The firm has also reported 4 ANDA filings during the Q1 June 2019 with cumulative ANDA filings of 165.
The company's managing director, Pranav Amin, said "It was a good quarter for the company backed by exceptional growth in the US market. Our Oncology Manufacturing Facility was inspected by the USFDA with no observations."
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app